Format

Send to

Choose Destination
Transl Oncol. 2018 Nov 15;12(2):282-291. doi: 10.1016/j.tranon.2018.10.013. [Epub ahead of print]

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis.

Author information

1
Department of Medicine (DIMED), University of Padua, Padua, Italy.
2
Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
3
Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
4
ARC-NET Research Center, University of Verona, Verona, Italy.
5
Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
6
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK; Department of Medicine, The Royal Marsden NHS Trust, London, UK.
7
Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
8
Department of Pathology, University of Ferrara, Ferrara, Italy.
9
Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
10
Department of Medicine, The Royal Marsden NHS Trust, London, UK; Molecular Pathology Division, Institute of Cancer Research, London and Sutton, UK. Electronic address: nicola.valeri@icr.ac.uk.

Abstract

miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive colorectal lesions was investigated for miR-224 expression by qRT-PCR and in situ hybridization. The caspase-3 and caspase-7 status was also assessed and correlated to miR-224 dysregulation. miR-224 was significantly upregulated during the adenoma-carcinoma sequence and in the context of inflammatory bowel disease dysplastic lesions, whereas its expression was significantly downregulated among BRAF-mutated tumors and in the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer, and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for BRAF-mutated/DNA mismatch repair-deficient tumors.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center